Pharmac notification: Decision to widen access to Amgevita, a citrate-free biosimilar adalimumab, and award Principal Supply
We are pleased to announce that we have made the decision to widen access to adalimumab and award Principal Supply to Amgevita, a citrate-free biosimilar adalimumab.
Please share this information
We want to make sure everyone who needs to know about this decision is aware of it. Please share this information with people you think might be interested.
Details about this decision
Information about this decision can be found on the Pharmac website.
We want to extend our thanks to everyone who took the time to respond to our consultation on this proposal.
Comments are closed.
Write something about yourself. No need to be fancy, just an overview.